GlassScriptPhysician profile
Brannon Anthony Treece
NPI 1588783666
$9,132.83
in general payments reported to CMS, 2019-2025
54 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $1,241 · 2021: $1,712 · 2022: $1,101 · 2023: $1,286 · 2024: $1,065 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,518.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,702.67 | 2019-2025 | |
| Abbvie INC. | $1,334.29 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $586.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $559.17 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $465.23 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $424.03 | 2019-2022 | |
| Allergan, INC. | $340.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $337.45 | 2019-2023 | Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $323.90 | 2020-2024 | |
| Novo Nordisk INC | $310.84 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $294.45 | 2019-2025 | Veozah |
| Lilly USA, LLC | $275.06 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $213.70 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $163.13 | 2021 | |
| Sunovion Pharmaceuticals INC. | $144.69 | 2019-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brannon Treece listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.